Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | CETP | P11597 | 3/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | MMP3 | P08254 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL160393 | 1.00 | MEN1 (0.42) | MEN1KMT2ADNM1EPHX2TP53 | |
| SCHEMBL4386268 | 1.00 | MEN1 (0.42) | MEN1KMT2ADNM1EPHX2TP53 | |
| SCHEMBL5301933 | 1.00 | MEN1 (0.42) | MEN1KMT2ADNM1EPHX2TP53 | |
| SCHEMBL9165455 | 1.00 | MEN1 (0.42) | MEN1KMT2ADNM1EPHX2TP53 | |
| SCHEMBL837479 | 1.00 | MEN1 (0.42) | MEN1KMT2ADNM1EPHX2TP53 | |
| SCHEMBL4650965 | 1.00 | MEN1 (0.42) | MEN1KMT2ADNM1EPHX2TP53 | |
| SCHEMBL427955 | 1.00 | MEN1 (0.42) | MEN1KMT2ADNM1EPHX2TP53 | |
| SCHEMBL3149218 | 1.00 | MEN1 (0.42) | MEN1KMT2ADNM1EPHX2TP53 | |
| SCHEMBL1703685 | 1.00 | MEN1 (0.42) | MEN1KMT2ADNM1EPHX2TP53 | |
| SCHEMBL5302396 | 1.00 | MEN1 (0.42) | MEN1KMT2ADNM1EPHX2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250034184-A1 | QUATERNARY PHOSPHONIUM COMPOUNDS AND USES THEREOF | EMORY UNIVERSITY (US) | 2025-01-30 | — | — | US | claimed |
| EP-4387628-A1 | QUATERNARY PHOSPHONIUM COMPOUNDS AND USES THEREOF | Emory University (US) | 2024-06-26 | — | — | EP | claimed |
| WO-2023023113-A1 | QUATERNARY PHOSPHONIUM COMPOUNDS AND USES THEREOF | EMORY UNIVERSITY (US) | 2023-02-23 | — | — | WO | claimed |
| CN-112079679-A | Asymmetric total synthesis method of sex pheromone (R, Z) -21-methyl-8-thirty-five carbene of longicorn | 塔里木大学 | 2020-12-15 | — | — | CN | claimed |
| US-20250034184-A1 | QUATERNARY PHOSPHONIUM COMPOUNDS AND USES THEREOF | EMORY UNIVERSITY (US) | 2025-01-30 | — | — | US | disclosed |
| US-20240277851-A1 | siRNA DELIVERY VECTOR | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2024-08-22 | — | — | US | disclosed |
| EP-4387628-A1 | QUATERNARY PHOSPHONIUM COMPOUNDS AND USES THEREOF | Emory University (US) | 2024-06-26 | — | — | EP | disclosed |
| US-11996557-B2 | Direct regeneration of lithium ion cathodes by ionothermal relithiation | UT-BATTELLE, LLC (US) | 2024-05-28 | — | — | US | disclosed |
| EP-4346902-A1 | SIRNA DELIVERY VECTOR | Council of Scientific & Industrial Research (IN) | 2024-04-10 | — | — | EP | disclosed |
| CN-117396227-A | siRNA delivery vectors | 科学与工业研究委员会 | 2024-01-12 | — | — | CN | disclosed |
| WO-2023023113-A1 | QUATERNARY PHOSPHONIUM COMPOUNDS AND USES THEREOF | EMORY UNIVERSITY (US) | 2023-02-23 | — | — | WO | disclosed |
| WO-2022265178-A1 | TRAP1 INHIBITOR AND USE THEREOF | 주식회사 스마틴바이오 | 2022-12-22 | — | — | WO | disclosed |
| US-5561020-A | THERMALLY STABLE, UNIFORMLY DISPERSIBLE | EASTMAN KODAK COMPANY (US) | 1996-10-01 | — | — | US | disclosed |
| US-5547803-A | Quaternary phosphonium trihalocuprate salts as charge-control agents for toners and developers | EASTMAN KODAK COMPANY (US) | 1996-08-20 | — | — | US | disclosed |
| EP-0718712-A1 | Quaternary phosphonium trihalocuprate salts as charge-control agents for toners and developers | EASTMAN KODAK COMPANY (US) | 1996-06-26 | — | — | EP | disclosed |
| EP-0718707-A1 | Quaternary phosphonium trihalozincate salts as charge-control agents for toners and developers | EASTMAN KODAK COMPANY (US) | 1996-06-26 | — | — | EP | disclosed |
| EP-0518973-B1 | ISOMERIZATION OF EPOXYALKENES TO 2,5-DIHYDROFURANS AND CATALYSTS COMPOSITIONS USEFUL THEREFOR | EASTMAN CHEM CO (US) | 1995-01-11 | — | — | EP | disclosed |
| US-4528404-A | High temperature hydroformylation in the presence of triarylphosphine rhodium carbonyl hydride complex catalyst systems | EXXON RESEARCH AND ENGINEERING CO. (US) | 1985-07-09 | — | — | US | disclosed |
| EP-0139702-A1 | HIGH TEMPERATURE HYDROFORMYLATION | EXXON RESEARCH AND ENGINEERING COMPANY (US) | 1985-05-08 | — | — | EP | disclosed |
| WO-1984003697-A1 | HIGH TEMPERATURE HYDROFORMYLATION | EXXON RESEARCH ENGINEERING CO (US) | 1984-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240277851-A1 | siRNA DELIVERY VECTOR | ATP5PD, SSBP1, MFN2 | MEN1 567/4885KMT2A 3890/4885DNM1 17/4885 |
| US-20250034184-A1 | QUATERNARY PHOSPHONIUM COMPOUNDS AND USES THEREOF | CD47, BTK, PHOSPHO1 | MEN1 809/4885KMT2A 711/4885DNM1 1866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.